These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 24263233)

  • 21. The PI3K/AKT pathway promotes gefitinib resistance in mutant KRAS lung adenocarcinoma by a deacetylase-dependent mechanism.
    Jeannot V; Busser B; Brambilla E; Wislez M; Robin B; Cadranel J; Coll JL; Hurbin A
    Int J Cancer; 2014 Jun; 134(11):2560-71. PubMed ID: 24374738
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FOXO1 Suppression is a Determinant of Acquired Lapatinib-Resistance in HER2-Positive Gastric Cancer Cells Through MET Upregulation.
    Park J; Choi Y; Ko YS; Kim Y; Pyo JS; Jang BG; Kim MA; Lee JS; Chang MS; Park JW; Lee BL
    Cancer Res Treat; 2018 Jan; 50(1):239-254. PubMed ID: 28343375
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dual EGFR/HER2 inhibitor lapatinib synergistically enhances the antitumor activity of the histone deacetylase inhibitor panobinostat in colorectal cancer models.
    LaBonte MJ; Wilson PM; Fazzone W; Russell J; Louie SG; El-Khoueiry A; Lenz HJ; Ladner RD
    Cancer Res; 2011 May; 71(10):3635-48. PubMed ID: 21464044
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Negative control of the HGF/c-MET pathway by TGF-β: a new look at the regulation of stemness in glioblastoma.
    Papa E; Weller M; Weiss T; Ventura E; Burghardt I; Szabó E
    Cell Death Dis; 2017 Dec; 8(12):3210. PubMed ID: 29238047
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
    Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
    Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.
    Wang X; Wong J; Sevinsky CJ; Kokabee L; Khan F; Sun Y; Conklin DS
    Mol Cancer Ther; 2016 Sep; 15(9):2198-208. PubMed ID: 27256378
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced PI3K p110α signaling confers acquired lapatinib resistance that can be effectively reversed by a p110α-selective PI3K inhibitor.
    Brady SW; Zhang J; Seok D; Wang H; Yu D
    Mol Cancer Ther; 2014 Jan; 13(1):60-70. PubMed ID: 24249715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Molecular mechanism of chemosensitization to paclitaxel in human melanoma cells induced by targeting the EGFR signaling pathway].
    Zhang XJ; Zhang L; Liu YP; Xu HM; Sun P; Song JG; Luo YH
    Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):181-6. PubMed ID: 23879997
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway.
    Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y
    Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacologic inhibition of mTOR improves lapatinib sensitivity in HER2-overexpressing breast cancer cells with primary trastuzumab resistance.
    Gayle SS; Arnold SL; O'Regan RM; Nahta R
    Anticancer Agents Med Chem; 2012 Feb; 12(2):151-62. PubMed ID: 22043997
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opposite regulation by PI3K/Akt and MAPK/ERK pathways of tissue factor expression, cell-associated procoagulant activity and invasiveness in MDA-MB-231 cells.
    Hu C; Huang L; Gest C; Xi X; Janin A; Soria C; Li H; Lu H
    J Hematol Oncol; 2012 Jul; 5():16. PubMed ID: 22534171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells.
    Mut M; Lule S; Demir O; Kurnaz IA; Vural I
    Int J Biochem Cell Biol; 2012 Feb; 44(2):302-10. PubMed ID: 22085529
    [TBL] [Abstract][Full Text] [Related]  

  • 33. miR-221 confers lapatinib resistance by negatively regulating p27
    Huynh TK; Huang CH; Chen JY; Yao JH; Yang YS; Wei YL; Chen HF; Chen CH; Tu CY; Hsu YM; Liu LC; Huang WC
    Cancer Sci; 2021 Oct; 112(10):4234-4245. PubMed ID: 34382727
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib.
    Normanno N; De Luca A; Maiello MR; Campiglio M; Napolitano M; Mancino M; Carotenuto A; Viglietto G; Menard S
    J Cell Physiol; 2006 May; 207(2):420-7. PubMed ID: 16419029
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insights into erlotinib action in pancreatic cancer cells using a combined experimental and mathematical approach.
    Lange F; Rateitschak K; Kossow C; Wolkenhauer O; Jaster R
    World J Gastroenterol; 2012 Nov; 18(43):6226-34. PubMed ID: 23180942
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf>MEK>ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK.
    Sambade MJ; Camp JT; Kimple RJ; Sartor CI; Shields JM
    Radiother Oncol; 2009 Dec; 93(3):639-44. PubMed ID: 19853943
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Restoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.
    Wu Z; Gioeli D; Conaway M; Weber MJ; Theodorescu D
    Prostate; 2008 Jun; 68(9):935-44. PubMed ID: 18386291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Grb7 upregulation is a molecular adaptation to HER2 signaling inhibition due to removal of Akt-mediated gene repression.
    Nencioni A; Cea M; Garuti A; Passalacqua M; Raffaghello L; Soncini D; Moran E; Zoppoli G; Pistoia V; Patrone F; Ballestrero A
    PLoS One; 2010 Feb; 5(2):e9024. PubMed ID: 20126311
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MEK inhibitors induce Akt activation and drug resistance by suppressing negative feedback ERK-mediated HER2 phosphorylation at Thr701.
    Chen CH; Hsia TC; Yeh MH; Chen TW; Chen YJ; Chen JT; Wei YL; Tu CY; Huang WC
    Mol Oncol; 2017 Sep; 11(9):1273-1287. PubMed ID: 28632938
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Evodiamine induces extrinsic and intrinsic apoptosis of ovarian cancer cells via the mitogen-activated protein kinase/phosphatidylinositol-3-kinase/protein kinase B signaling pathways].
    Wei L; Jin X; Cao Z; Li W
    J Tradit Chin Med; 2016 Jun; 36(3):353-9. PubMed ID: 27468551
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.